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Abstract
Background: Folic acid (FA) supplementation before and during the first trimester can reduce the risk of
occurrence of preterm delivery (PTD). Preconception body mass index (BMI) is also associated with PTD. This study
aimed to investigate the combined effect of FA supplements and preconception BMI on the risk of PTD.
Methods: The data of a cohort from 2010–2011 that was obtained through a preconception care service in China
was used (including 172,206 women). A multivariable regression model was used to investigate the association
between maternal preconception conditions and the risk of PTD. The interaction of preconception BMI and FA
supplementation was measured by a logistic regression model.
Results: Taking FA supplements in the preconception period or in the first trimester reduced the risk of PTD (odds
ratio [OR] = 0.58 and OR = 0.61, respectively). Women with an abnormal BMI had an increased risk of PTD (OR = 1.09,
OR = 1.10, and OR = 1.17 for underweight, overweight, and obese, respectively). Preconception BMI showed an interaction
with the protective effect of FA supplementation for PTD. With regard to the interaction of FA supplementation, the
adjusted odds ratio (aOR) was 0.57 (95 % CI: 0.51, 0.64) in underweight women, 0.85 (95 % CI: 0.73, 0.98) in overweight
women, and 0.77 (95 % CI, 0.65, 0.91) in obese women. Preconception BMI also showed an interaction with the time of
FA supplementation. Women with a normal BMI who began to take FA supplements in the preconception period had
the lowest risk of PTD (aORs: 0.58 vs. 0.65 beginning in the first trimester). The aORs at preconception and the first
trimester in the underweight group were 0.56 vs. 0.60. The aORs at preconception and the first trimester were 0.94 vs.
0.65 and 1.15 vs. 0.60 in the overweight and obesity groups, respectively.
Conclusions: In our study, FA supplements reduced the risk of PTD, while abnormal BMI raised the risk of PTD,
although higher BMI categories did not have this higher risk once adjusted analysis was conducted. The protective
effect of FA supplementation for PTD was reduced in women with overweight or obesity. To get better protection of
FA supplementation, women with normal BMI or underweight should begin to use in preconception, while women
with overweight or obesity should begin to use after conception.
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Background
Preterm delivery (PTD) is defined as neonates who are
born alive before 37 weeks of pregnancy are completed.
PTD is the second largest direct cause of child deaths in
children younger than 5 years and causes approximately
1 million deaths annually worldwide. Additionally, PTD
causes lifelong problems for many survivors [1].
The incidence of PTD was 7.1 % in a multicenter,
hospital-based investigation (based on 107,905 deliver-
ies) in China. The proportion of PTD among the causes
of neonatal death has significantly increased from 33.6 %
in 2003 to 40.9 % in 2008. PTD is the leading cause of
neonatal death in China [2]. Because of the large popula-
tion in China, China has become the second largest
country with annual preterm deliveries. PTD is a serious
public health problem in China.
PTD is thought to be a syndrome that is initiated by
multiple mechanisms. However, the precise mechanism of
PTD has not been established. Therefore, factors associ-
ated with preterm birth, but not obviously in the causal
pathway, have been sought to explain preterm labor.
Folic acid (FA), an oxidized synthetic water-soluble mem-
ber of the vitamin-B complex family, plays an essential role
in one-carbon metabolism. The clinical application of FA
supplementation to prevent neural tube defects (NTD) had
been well proven in the last 20–25 years. Pregnant women
are at risk of folate deficiency because pregnancy greatly
increases folate requirements, especially during periods of
rapid fetal growth (i.e., in the second and third trimesters).
Although the relation between maternal folate status with
NTD has been well established [3, 4], the association of
folate status with other adverse pregnancy outcomes is still
unclear [5]. Recently, some researchers have investigated
maternal FA supplementation and PTD, but the findings
were largely inconclusive. Some results supported protect-
ive effects [6–9] and some did not [10–14, 15]. A large
population-based cohort study conducted in China showed
that daily intake of 0.4 mg folic acid reduced the risk of
PTD [6]. A cohort in Singapore showed that higher plasma
folate concentrations were associated with a longer
gestational age and tended to be associated with a lower
risk of PTD [16]. Similar results were obtained in some
prospective observational studies in the USA [17, 18]. Some
researches have shown that maternal FA supplementation
during pregnancy protects against lipopolysaccharide-
induced PTD through its anti-inflammatory effects
[19–21]. Researchers have hypothesized that lower ma-
ternal serum folate concentrations during pregnancy is
associated with higher maternal plasma homocysteine
concentrations, which cause pre-eclampsia and affect
placental function, eventually leading to PTD [22, 23].
Abnormal preconception body mass index (BMI) is a
risk factor for PTD [24, 25, 26]. The spontaneous PTD
rate is higher in pre-pregnancy underweight women
(BMI <18.5 kg/m2) than in normal-weight women [27,
28]. Some researchers have found that indicated PTD
and premature rupture of the membranes are associated
with preconception obesity, especially in extremely obese
groups [27, 29]. Obese women are more likely to de-
velop pre-eclampsia and diabetes, and have indicated
preterm births associated with these disorders [30]. In a
Boston birth cohort, pre-pregnancy obesity was associ-
ated with a decreased odds of PTD (0.76) and under-
weight was nearly associated with an increased odds of
PTD (1.46) for spontaneous delivery [30].
Maternal BMI and FA supplementation can affect the
risk of PTD. Some studies have shown that there is an
inverse interaction between BMI and serum folate levels
[31, 32]. Distribution of folate in the body is significantly
affected by obesity, and should pregnancy occur, it may
reduce the amount of folate available to the developing
embryo [33–35]. The FA supplement guideline in
Canada suggests that women with a BMI >35 kg/m2
should take 5-mg folate supplements daily to prevent a
poor outcome [36].
Whether there is any interactive effect between precon-
ception BMI and FA supplementation for PTD is unclear.
These previous studies mentioned above were mostly
based on Caucasians, and there is a lack of Chinese popu-
lation data. In this study, we aimed to determine whether
FA supplementation can reduce the risk of PTD in China.
We also investigated whether there is an interaction
between FA supplementation and maternal BMI for the
risk of PTD in the Chinese population.
Methods
Study design
This study was designed as a retrospective cohort study.
From 2010, the free National Pre-pregnancy Checkups
Project (NPCP) for rural women was carried out, which
collected the largest pregnancy cohort data from the
preconception stage in China. The NPCP is a population-
based, free, preconception medical examination and
services for rural reproductive-age couples who are trying
to conceive in China. The NPCP covers couples who are
preparing for pregnancy, from a preconception examin-
ation to pregnancy outcome follow-up. In 2010, the NPCP
was first carried out in a 100-district region in China. In
this study, examination data of the 100 districts in 2010
was used. The 100 districts are distributed throughout 18
provinces, including four provinces in eastern China
(Jiangsu, Zhejiang, Shandong, and Guangdong), six
provinces in central China (Hebei, Jilin, Anhui, Henan,
Hubei, and Hunan), and eight provinces in western China
(Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Shanxi,
Gansu, and Xinjiang). The total population of the research
area in 2010 was 7.16 million (females, 3.49 million; males,
3.67 million, approximately 5 % of the total population of
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China [37]). The rural population in the 100 districts was
4.76 million (66 % of the total population). Rural couples
trying to conceive who lived in these areas could receive a
free medical checkup in county-level medical institutions
from January 2010 to December 2010 in the project. The
clinical data were collected during the preconception
medical examination. Information on socioeconomic
background, reproductive history and history of illness,
lifestyle behaviors, and dietary habits were carefully
collected through face-to-face interviews by qualified
nurses. Physical and biochemical examinations were
also carried out by medical staff at the same time,
including measurement of maternal height, weight,
blood pressure, and hemoglobin levels.
After the examination, the couples received two follow-
up interviews. The first interview was a telephone interview
carried out by a trained nurse 3 months after conception.
This interview was designed to obtain information of the
last menstrual period and FA supplement use status
(including the time when first taking FA). The second
interview was carried out face-to-face or by telephone
1 month after delivery. Newborn information was
collected by a trained interviewer according to the
participants’ answers. The current study was conducted
in accordance with the Declaration of Helsinki (2000)
of the World Medical Association and the protocols
were approved by the Institutional Research Review
Board at the National Population and Family Planning
Commission. Informed consent in Chinese was obtained
from all NFPC participants.
Study population
Couples who attended the preconception medical examin-
ation and obtained successful conception within 6 months
in the cohort were eligible (200,165). A total of 19,398
participants were excluded because of missing data, lost to
follow-up, abortion (spontaneous or induced), and stillbirth.
Women with post-term pregnancy (≥42 weeks) and
multiple pregnancies were not included in the study (8561).
Finally, 172,206 pregnancies were selected for analysis
(Fig. 1).
Definition of variables
The outcome variable in this analysis was PTD, which was
defined as neonates who were born alive before 37 weeks
of pregnancy were completed. Gestational age was calcu-
lated from the last menstrual period and the birth date.
The independent variables were those expected to be asso-
ciated with PTD based on current literature [38], including
pertinent health variables (maternal preconception BMI,
anemia, diabetes, and hypertension), pregnancy history,
health behavior, and demographic variables. Preconception
BMI (kg/m2) was calculated using maternal weight and
height during the preconception physical examination.
Because the participants in this study were all Chinese
women, Chinese BMI classification standards were used in
this study to classify different BMI groups. BMI <18.5 was
considered underweight, BMI ≥18.5 and <24 was consid-
ered normal, BMI ≥24 and <28 was considered overweight,
and BMI ≥28 was considered obese according to the
Chinese population standards [39, 40].
FA supplementation was based on self-reported use
in the first interview. FA supplementation was defined
as women who had used supplements and had either
taken FA alone or multivitamins (containing FA). FA
supplement information was obtained in the first
trimester follow-up. Therefore, we divided FA supple-
mentation into three groups according to the time
when the participants began to take FA: none, after
conception, and preconception. Hypertension was
defined as high blood pressure in the preconception
examination (SBP ≥140 mmHg or DBP ≥90 mmHg)
and self-reported hypertension. Diabetes was defined as
self-reported diabetes or blood sugar ≥7 mmol/L. Anemia
was defined as hemoglobin levels <110 g/L when the
participant took the biochemical examination in the
preconception service. Preconception dietary habits were
defined as risk factors based on the self report, such as
“dislike vegetables” and “vegetarian”, which indicated
“seldom eat meat and eggs”. Tobacco use was defined as
smoking at least one cigarette per day for at least 1 year in
current smokers.
Statistical analysis
All analyses were generated using SAS software (version
8.2, SAS Institute Inc., North Carolina). The general
characteristics of mothers and children based on differ-
ent categories of maternal preconception BMI and FA
supplementation were compared using the chi-squared
test and t-test. Logistic regression was used to estimate
the crude odds ratio (cOR) and the adjusted odds ratio
(aOR) with 95 % confidence intervals (CIs) of PTD [41].
Covariates in the multivariable models included demo-
graphic factors (maternal age, education level, ethnic group,
and career) and preconception risk factors (hypertension,
anemia, alcohol use). The time of FA supplement was
calculated by setting the dummy variable. The effect of FA
supplementation of different weight group was calculated
through the contrasts estimated in the model. A significant
p value was set at 0.05.
Results
The mean age of the participants was 24.98 ± 3.87 years
and the mean gestational age was 39.14 ± 1.67 weeks.
The mean BMI was 21.03 ± 5.39 kg/m2. A total of 9573
infants were born PTD. 159,635 (92.7 %) mothers were
21–35 years old, 163,767 mothers were Han ethnic
(95.1 %), and 163,423 had at least a junior or higher
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school education (94.9 %). The proportion of FA supple-
mentation was 76.8 % and the proportion of an abnor-
mal BMI (obese, overweight, and underweight) was
24.5 %. We compared maternal characteristics grouped
by preconception BMI and FA supplementation status.
Overweight or obese women were more likely to have
hypertension or diabetes at preconception than women
with a normal BMI or underweight women (Table 1).
The proportion of women with high school or higher
education experience was higher in women using FA
than in nonusers. More population characteristics are
shown in Table 1.
Women with an abnormal BMI had an increased risk of
PTD (OR= 1.09, OR = 1.10, and OR = 1.17 for under-
weight, overweight, and obese, respectively). Preconception
disease also raised the risk of PTD (OR= 1.49 and OR =
1.19 for hypertension and anemia, respectively). Women
using alcohol had a higher risk of PTD (OR= 1.24). The
risk of PTD was decreased by taking FA supplements, and
this phenomenon was time-related. Taking FA supplements
in the preconception period or in the first trimester
reduced the risk of PTD (OR = 0.58 and OR = 0.61, respect-
ively). The difference between the preconception period
and the first trimester was not significant by transforming
the first trimester as the reference group (p = 0.053). Details
were listed in Table 2.
An interaction effect was found between preconception
BMI and FA supplementation for PTD (Table 3). Taking
FA supplements reduced the risk of PTD in all groups.
Non-users with a normal BMI had a baseline risk of 7.95
PTD births per 100 live births, whereas mothers who took
FA supplements had 4.69 PTD births per 100 live births
(OR = 0.60). The OR of FA supplementation varied in dif-
ferent BMI groups. In underweight group, the OR of FA
was 0.57 (95 % CI: 0.51, 0.64); in overweight group, the
OR was 0.85 (95 % CI: 0.73,0.98); in obese group, the OR
was 0.77 (95 % CI: 0.65,0.91). The interaction between
maternal BMI and time of FA supplements was compared
to examine why the protective effect was different among
different BMI groups. We found that the protective effect
of FA supplement in women with normal or underweight
had similar values. The effect of FA supplement was dif-
ferent in overweight and obesity group, especially in pre-
conception. Women with a BMI <24 kg/m2 (including
normal and underweight groups) who took FA supple-
ments from preconception had a lower risk for PTD than
in the first trimester (OR: 0.58 vs. 0.65 in the normal
weight group, 0.56 vs. 0.60 in the underweight group).
Women with a BMI ≥24 kg/m2 (including the overweight
and obese groups) who took FA supplements from the
first trimester had a lower risk of PTD than at preconcep-
tion (OR: 0.65 vs. 0.94 in the overweight group, 0.60 vs.
1.15 in the obesity group). Compared with no takers,
obese women took FA supplement in preconception had
an OR of 1.15 (not statistical significant).
Discussion
In our research population, the proportion of FA supple-
mentation was as high as 76.8 % and more than 50 %
women began to take FA supplements before conception.
Fig. 1 Flowchart of participant recruitment
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The reason for the high rate of supplementation in this
population was based on a nation-wide free FA supple-
mentation program, which was implemented in rural
areas of China since 2009. The Chinese guideline of FA
supplements is 0.4 mg/d from preconception to the end of
the first trimester. Women who had rural household
Table 1 Maternal characteristics in study population grouped by preconception body mass index and folic acid supplement
Preconception body mass index(kg2) P Folic acid supplement P
<18.5 18.5-23.9 24-27.9 ≥28 Never 1st trimester Preconception
Maternal characteristics
No of subject 23429 129982 15880 2915 39871 41457 90878
Demographic information (%)
Maternal age (yr) 24.96(3.19) 24.18(3.82) 26.01(4.54) 26.60(4.70) <0.001 24.85(3.94) 24.77(3.69) 25.13(3.90) <0.001
Maternal education level
Primary school 4.72 4.96 6.78 8.03 <0.001 5.01 4.51 5.50 <0.001
Junior school 60.56 67.38 71.79 72.42 73.50 63.63 65.57
High school 21.82 18.81 15.29 14.68 15.35 20.68 19.51
College and above 12.89 8.85 6.13 4.87 6.14 11.18 9.42
House wife
Yes 2.60 2.21 2.15 2.06 0.002 2.11 2.41 2.24 0.013
No 97.40 97.79 97.85 97.94 97.89 97.59 97.76
Chinese Ethnic group
Chinese Han 95.36 95.02 95.41 95.64 0.015 94.98 96.47 94.55 <0.001
Others 4.64 4.98 4.59 4.36 5.02 3.53 5.45
Maternal risk factors (%)
Previous preterm delivery
No 99.75 99.83 99.62 99.59 <0.001 99.79 99.83 99.78 0.239
Yes 0.25 0.17 0.38 0.41 0.21 0.17 0.22
Preconception hypertension
No 98.41 97.99 95.74 90.05 <0.001 97.29 98.08 97.71 <0.001
Yes 1.59 2.01 4.26 9.95 2.71 1.92 2.29
Anemia
No 84.54 85.99 85.21 87.38 <0.001 83.98 83.41 87.58 <0.001
Yes 15.46 14.01 14.79 12.62 16.02 16.59 12.42
Diabetes mellitus
No 98.34 98.77 98.05 96.84 <0.001 98.63 98.28 98.76 <0.001
Yes 1.66 1.23 1.95 3.16 1.37 1.72 1.24
Dislike vegetables
No 99.24 99.37 99.17 99.11 0.004 99.27 99.34 99.34 0.286
Yes 0.76 0.63 0.83 0.89 0.73 0.66 0.66
Preconception alcohol use
No 96.79 97.01 97.20 97.32 0.080 97.43 96.83 96.89 <0.001
Yes 3.21 2.99 2.80 2.68 2.57 3.17 3.11
Preconception Tobacco use
No 99.63 99.70 99.57 99.31 <0.001 99.70 99.58 99.70 0.001
Yes 0.37 0.30 0.43 0.69 0.30 0.42 0.30
Preterm delivery
No 94.11 94.57 94.05 93.69 0.001 92.08 94.98 95.23 <0.001
Yes 5.89 5.43 5.95 6.31 7.92 5.02 4.77
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registration and planned to become pregnant were eligible
to obtain FA tablets containing 0.4 mg FA for 6 months at
no charge [42].
A negative association was found between FA supple-
mentation and the risk of PTD in our population. FA
supplementation showed a strong protective effect on
PTD. This protective rate varied from 35 % to 40 %
according to different supplementation times. Women
who began to take FA supplements in the preconception
period had the lowest risk of PTD (cOR = 0.58, details in
Table 2). Similar results were reported in the USA,
where the duration of preconceptional folate supplemen-
tation affected the protective effect for PTD. In a meta-
analysis, many observational studies suggested a slight
reduction in PTD, which was not consistent with the
results from randomized, controlled trials [43]. The risk
of spontaneous preterm birth decreased with the dur-
ation of preconceptional folate supplementation, and
taking FA supplements over 1 year could reduce the risk
of early spontaneous preterm birth by 50–70 %. In
contrast, a cohort of Norwegians showed the opposite
result, where preconceptional FA supplementation start-
ing more than 8 weeks before conception was associated
with an increased risk of PTD (hazard ratio = 1.19) [44].
Another study showed a 20 % lowered risk of PTD was
found in the first trimester compared with preconcep-
tion [33].
In our population, we found that women who were
underweight/overweight/obese were at increased risk of
PTD in single risk factor analysis (Table 2). Similar results
were also reported in the USA and India [29, 45, 46].
Spontaneous preterm birth could be caused by maternal
Table 2 Crude odds ratio (95 % confidence intervals) of preterm
delivery by maternal characteristics and single risk factor
Number PTD
% cOR (95 % CI) P value
Maternal characteristics
Maternal age
≤ 20 years 8844 5.89 1.07 (0.98,1.17) 0.14
21–35 years 159640 5.53 1
> 35 years 3722 6.18 1.13 (0.98,1.29) 0.09
Maternal education level
Primary school and below 8866 4.87
Junior school 115279 6.02 1.25 (1.13,1.38) <0.01*
High school 32418 4.42 0.90 (0.81,1.01) 0.07
College and above 15643 4.88 1 (0.89,1.13) 0.97
Maternal career
House wife 3878 7.01 1
Others 168328 5.53 1.29 (1.14,1.46) <0.01*
Chinese Ethnic group
Chinese Han 163786 5.67 1
Others 8420 3.46 0.60 (0.53,0.67) <0.01*
Maternal risk factors
Previous preterm delivery
No 171852 5.56 1
Yes 354 6.78 1.24 (0.82,1.87) 0.32
Preconception BMI
Underweight 23429 5.89 1.09 (1.03,1.16) <0.01*
Normal weight 129982 5.43 1
Overweight 15880 5.95 1.10 (1.03,1.18) 0.01*
Obese 2915 6.31 1.17 (1.01,1.36) 0.04*
Preconception hypertension
No 168248 5.5 1
Yes 3958 7.98 1.49 (1.33,1.67) <0.01*
Anemia
No 147657 5.42 1
Yes 24549 6.37 1.19 (1.12,1.25) <0.01*
Diabetes mellitus
No 169819 5.55 1
Yes 2387 6.12 1.11 (0.94,1.31) 0.23
Folic acid supplement
Never 39871 7.92 1
1st trimester 41457 5.02 0.61(0.58,0.65) <0.01*
Preconception 90878 4.77 0.58(0.56,0.61) <0.01*
Dislike vegetables
No 171047 5.55 1
Yes 1159 6.47 1.18(0.93,1.49) 0.17
Preconception alcohol use
Table 2 Crude odds ratio (95 % confidence intervals) of preterm
delivery by maternal characteristics and single risk factor
(Continued)
No 167040 5.52 1
Yes 5166 6.78 1.24 (1.11,1.39) <0.01*
Preconception tobacco use
No 171641 5.56 1
Yes 565 6.19 0.85 (0.58,1.25) 0.42
Note: cOR = crude odds ratio
Table 3 Effect of FA supplement in different BMI group for PTD
BMI group FA supplement OR (95 % CI)
No Yes 1st trimester Preconception
Normal ref 0.60 (0.57,0.63) 0.65 (0.61,0.69) 0.58 (0.55,0.62)
Underweight ref 0.57 (0.51,0.64) 0.60 (0.52,0.69) 0.56 (0.49,0.63)
Overweight ref 0.85 (0.73,0.98) 0.65 (0.53,0.79) 0.94 (0.80,1.10)
Obesity ref 0.77 (0.65,0.91) 0.60 (0.37,0.97) 1.15 (0.81,1.64)
Note: Adjusted for maternal education, career, ethnic, hypertension, anemia,
alcohol use
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thinness associated with decreased blood volume and
fewer vitamins and minerals, which are associated with
increased maternal infections. Serum folate levels are
lower in obese women than in normal or underweight
women [32]. Obese women are more likely to develop
pre-eclampsia and diabetes, and indicated preterm births
are associated with these disorders [42]. In this study,
we could only compare the interaction between FA
supplementation and maternal BMI. The direct factor
(folate levels) in the population was not compared
(without original data). FA supplementation can re-
duce homocysteine, which causes pre-eclampsia and
affects placental function and fetal maturity, eventu-
ally leading to PTD. Therefore, analyzing the inter-
action of FA and BMI for prevention of PTD is
important.
An interaction between FA supplements and maternal
BMI was found in our population, and the protective effect
of FA varied in different BMI groups. Taking FA supple-
ments of 0.4 mg/d (regardless of when they started)
reduced the risk of PTD in all of the BMI groups. The time
of taking FA supplement was very important in women
with abnormal BMI. In the underweight group, there was
very little difference between 1st trimester and preconcep-
tion. But in overweight and obesity group, the difference
was very large. We hypothesize that maternal body size is
associated with folate metabolism, which can influence
maternal homocysteine levels and affect embryonic devel-
opment and gestational weeks [23, 47]. Distribution of
folate in the body is significantly affected by BMI, and obes-
ity might reduce the amount of folate available to the devel-
oping embryo [35, 36]. Obesity-associated metabolic
alterations could have an effect on folate use or increase
folate requirements [48, 49]. RBC folate increased incre-
mentally with BMI, while serum folate concentrations were
lower in obese groups [50]. We conclude that FA supple-
mentation and maternal obesity can influence homocyst-
eine levels, which might affect placental function and
eventually lead to PTD. The distribution of folate might be
changed in pregnancy period. We also compared the inter-
action between the time of FA supplements and maternal
BMI. Women with a BMI <24 kg/m2 (including the normal
and underweight groups) who took FA supplements from
preconception had a lower risk for PTD than in the first
trimester. Women with a BMI ≥24 kg/m2 (including the
overweight and obese groups) who took FA supplements
from the first trimester had a lower risk of PTD than at
preconception. Several studies have shown that different
supplementation times can change the protective effect of
FA [9, 51]. In a similar study on NTD, the protective of FA
was also weaker in the overweight and obesity population
than in the normal and underweight population [52]. We
suggest that a diverse plan of FA supplementation should
be carried out according to women’s BMI category. The
time and dose of FA supplement for obesity should be
taken into account.
Limitations
The primary limitation in the present study was misclassifi-
cation of FA supplemental status. We relied on the self-
reported use of FA supplements, which could lead to
misclassification of FA supplemental status. We compared
the proportion of FA supplements in our study with other
studies (77 % vs. 68–92 % [47, 53]). The name and content
of the FA supplement was not investigated in the first
trimester interview. Therefore, we could not separate FA
supplements and multiple vitamin supplements, including
FA. Dietary folate was also not estimated in this cohort. We
could not calculate the exact folate level. Further research
should be carried out to verify the results of this study.
The second limitation of this study was that PTD
could not be divided into indicated and spontaneous
PTD. Pre-pregnancy obesity is associated with a higher
risk of indicated, but not spontaneous, PTD [30]. This
study was a retrospective cohort study. We could not
analyze the risk of iatrogenic PTD because this type of
PTD was not classified in the follow-up records.
Detailed data should be collected to estimate the pro-
tective effect of FA between indicated PTD and spontan-
eous PTD in the future.
Because of the uncertainty of natural conception, we
selected women who became pregnant in the following
6 months after the preconception medical examination
as our research population. All statistical research was
carried out in this population, which could also have
reduced the effect of a change in maternal medical
status on the results. Reported supplementation of FA
for 1 year prior to conception has been linked with a
decreased risk of preterm birth [54]. In our cohort, we
did not test the protective effect of FA from 1 year
before conception in our population. Because our
study design only included 6 months of FA supple-
ments in the pregnant population, the results may not
apply to the whole population.
Conclusions
In our study, FA supplements reduced the risk of PTD,
while abnormal BMI raised the risk of PTD, although
higher BMI categories did not have this higher risk once
adjusted analysis was conducted. The protective effect of
FA supplementation for PTD is reduced in women
whose BMI was equal or greater than 24 kg/m2. To get
better protection of FA supplementation, women with
BMI < 24 kg/m2 should begin to use in preconception,
while women with BMI ≥24 kg/m2 should begin to use
after conception.
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